TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03599401

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and root planing
Description: Scaling and root planing was done by using ultrasonic scalers with high speed suction apparatus to prevent aerosol contamination.~.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and root planing
Description: Scaling and root planing was done by using ultrasonic scalers with high speed suction apparatus to prevent aerosol contamination.~.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Scaling and root planing
Description: Scaling and root planing was done by using ultrasonic scalers with high speed suction apparatus to prevent aerosol contamination.~.
Study: NCT00477581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: subcutaneous injection (5mcg or 10mcg), twice a day
Study: NCT01127204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABC-3TC-EFV once a day
Description: ABC sirup (20mg/ml): 16 mg/kg once daily in the morning 3TC sirup (10mg/ml): 8 mg/kg once daily in the morning EFV sirup (30mg/ml): 25 mg/kg once daily in the morning before food intake
Study: NCT00477581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: subcutaneous injection (5mcg or 10mcg), twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin
Description: oral administration (100mg), once a day in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin
Description: oral administration (100mg), once a day in the morning
Study: NCT01740843

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS) (NeuroConn DC-stimulator)
Description: The anode is fixed on the primary cortex and the cathode will be fixed on the contralateral supraorbital region.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS) (NeuroConn DC-stimulator)
Description: The anode is fixed on the primary cortex and the cathode will be fixed on the contralateral supraorbital region.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS) (NeuroConn DC-stimulator)
Description: The anode is fixed on the primary cortex and the cathode will be fixed on the contralateral supraorbital region.
Study: NCT02594540

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical Peripheral Stimulation (GONDOLA)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Mechanical Peripheral Stimulation (GONDOLA)
Study: NCT02438306

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous cell therapy
Description: Autologous cell therapy delivered into the heart muscle using the CardiAMP Cell Therapy System. The CardiAMP Cell Therapy System consists of the CardiAMP Cell Separator, a cardiac delivery catheter, and flexible tip guide catheter.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: An introducer guidewire is placed into the heart and left ventriculography is performed just like it is in the Experimental Arm but no autologous cell therapy is delivered.
Study: NCT02843308

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facilitated group therapy with behavioral practice; 18 weeks
Description: Facilitated group therapy for hoarding disorder with behavioral practice

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facilitated group therapy with behavioral practice; 18 weeks
Description: Facilitated group therapy for hoarding disorder with behavioral practice
Study: NCT03464058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS172767 liquid capsules
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS172767 liquid capsules
Description: Oral capsules
Study: NCT03960554

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab Inj 60 mg/ml
Description: Treatment will be administered by study personnel as a subcutaneous injection every 6-months for one year.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered by study personnel as a subcutaneous injection every 6-months for one year.
Study: NCT00920231

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: initial system
Description: The computer vision system is used to assist blind subject to navigate an extended path with multiple turns within a hospital setting.The initial prototype system would have been successfully tested for outdoor navigation and basic object recognition tasks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: modified system
Description: The problems associated with the initial system were identified and modified. This modified system was tested with a second separate group of subjects. The redesigned system is used to assist blind subject to navigate the same extended path with multiple turns within a hospital setting.
Study: NCT02597634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SST-0225
Description: SST-0225 is a cream formulation for topical application. Each 5.4 g dose is formulated to topically deliver 400 mg of ibuprofen. The cream contains sodium ibuprofen and various salts.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IP will be the same vehicle as SST-0225 vehicle without the active ingredient, ibuprofen. It will be matched in appearance, smell, consistency, and color to SST-0225 topical ibuprofen cream.
Study: NCT04744038

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positive Airway Pressure (PAP) Therapy
Description: PAP therapy supplies pressurized air from the flow generator to the upper airway via air tubing and a mask to prevent the repetitive collapse of the upper airway during sleep.
Study: NCT03812432

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near-infrared fluorescence cholecystocholangiography
Description: Device: Real-Time Fluorescence Imaging (VISERA ELITE II Imaging System). These device is used to identify anatomy, using infrared light that causes the indocianine green to fluoresce.
Study: NCT03120442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: target-controlled infusion starting for Cet 0.1 mcg/ml to achieve MOAA/S 3-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Incremental titration of dexmedetomidine starting from 0.1 mcg/kg/hr to achieve MOAA/S 3-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: 0.25 mcg fo Fentanyl for anxiolysis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: 0.25 mcg fo Fentanyl for anxiolysis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: 0.25 mcg fo Fentanyl for anxiolysis
Study: NCT03239964

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: the wound edges are injected once with dexamethasone. A 1 mL syringe with a 30-gauge needle is used and injection is both intradermal and subdermal. Repeated alternate punctures are used to bathe the wound edges with the drug. Approximately 0.5-1 mL of dexamethasone (4 mg/mL) in wound tissue.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: surgical excision
Description: total extralesional surgical excision of the keloid is performed and minimal undermining

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: surgical excision
Description: total extralesional surgical excision of the keloid is performed and minimal undermining
Study: NCT02316912

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATX2417
Description: Randomised double blind parallel group ascending dose assessment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATX2417
Description: Randomised double blind parallel group ascending dose assessment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATX2417
Description: Randomised double blind parallel group ascending dose assessment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATX2417
Description: Randomised double blind parallel group ascending dose assessment
Study: NCT00827307

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamoxifen
Description: In the monotherapy arm, patients receive once-daily oral dose of tamoxifen 20 mg.
Study: NCT02316912

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATX2417
Description: Randomised double blind parallel group ascending dose assessment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATX2417
Description: Randomised double blind parallel group ascending dose assessment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATX2417
Description: Randomised double blind parallel group ascending dose assessment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATX2417
Description: Randomised double blind parallel group ascending dose assessment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATX2417
Description: Randomised double blind parallel group ascending dose assessment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Randomised double blind parallel group ascending dose assessment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Randomised double blind parallel group ascending dose assessment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Randomised double blind parallel group ascending dose assessment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Randomised double blind parallel group ascending dose assessment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Randomised double blind parallel group ascending dose assessment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Randomised double blind parallel group ascending dose assessment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Randomised double blind parallel group ascending dose assessment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Randomised double blind parallel group ascending dose assessment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Randomised double blind parallel group ascending dose assessment
Study: NCT00412490

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Written survey at 1 Month \& 6 Months post surgery.

Intervention type: BEHAVIORAL
Intervention: Interview
Description: One-on-One meeting lasting about one hour, at 1 Month \& 6 Months post surgery.
Study: NCT03614767

Intervention type: DIAGNOSTIC_TEST
Intervention: urodynamics
Description: Bladder filling and pressure is measured by the insertion of probes within the bladder, urethra and anorectum.

Intervention type: DIAGNOSTIC_TEST
Intervention: urodynamics
Description: Bladder filling and pressure is measured by the insertion of probes within the bladder, urethra and anorectum.
Study: NCT03149393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qizhi Weitong Granules
Description: Patients in this group will take Qizhi Weitong Granules 2.5g,3 times/day,30 minutes before dinner for 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mosapride Citrate Tablets
Description: Patients in this group will take mosapride citrate tablets 5mg,3 times/day,30 minutes before dinner for 8 weeks.
Study: NCT02122731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiloride
Description: 5 mg(daily of amiloride was added to patients triple antihypertensive therapy and increased to 10 mg/daily if office blood pressure at 4 weeks was above 130/80 mmHg.
Study: NCT03853798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-348
Description: Participants will receive 5, 20, or 50 mg twice a day for up to 192 weeks (not including dose taper) unless the dose is modified for reasons related to safety.
Study: NCT02791958

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril 10 mg
Description: A once daily oral dose of ramipril 10 mg (Altace®) for 4 weeks
Study: NCT01408888

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY2189265
Description: Administered subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY2189265
Description: Administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Administered orally
Study: NCT04122027

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cerebral oximeter
Description: Near infra-red spectroscopy, NIRS

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cerebral oximeter
Description: Near infra-red spectroscopy, NIRS
Study: NCT04025398

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive remediation program
Description: Comparison between a cognitive remediation program (REHABILITUS) (group 1) and a training group of manual activities (group 2)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Comparison between a cognitive remediation program (Réhabilitus) (group 1) and a training group of manual activities (group 2)
Study: NCT00201136

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle interventions to lower blood pressure for patients
Description: Weight loss, DASH dietary pattern, increased physical activity, reduced salt intake, moderation of alchohol intake.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle interventions to lower blood pressure for patients
Description: Weight loss, DASH dietary pattern, increased physical activity, reduced salt intake, moderation of alchohol intake.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MD CQI-type intervention
Description: CQI-type intervention for MD adherence to JNC guidelines for BP management

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MD CQI-type intervention
Description: CQI-type intervention for MD adherence to JNC guidelines for BP management
Study: NCT03464058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS172767 liquid capsules
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS172767 liquid capsules
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS172767 liquid capsules
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS172767 micronized capsules
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS172767 micronized capsules
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS172767 micronized capsules
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS172767 micronized capsules
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS172767 micronized capsules
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS172767 micronized capsules
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS172767 micronized capsules
Description: Oral capsules
Study: NCT04554186

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serratus anterior plane block
Description: Injection of bupivacaine between serratus anterior plane and latissimus dorsi muscle using ultrasound
Study: NCT00117377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimecrolimus
Description: Pimecrolimus cream 1 % bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo application bid
Study: NCT02408419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Bupivacaine is injected proximally to anesthetize the obturator nerve

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline is injected as a placebo
Study: NCT03670186

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Description: Participants perform high-intensity interval training (HIIT) on a cycle ergometer. The HIIT protocol consists of a 3-minute warm-up at 50W, ten 60-second high-intensity cycling intervals interspersed with 90 seconds of active recovery at 30% of their peak power output and a 2-minute cool-down at 50W for a total of 17.5 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Description: Participants perform high-intensity interval training (HIIT) on a cycle ergometer. The HIIT protocol consists of a 3-minute warm-up at 50W, ten 60-second high-intensity cycling intervals interspersed with 90 seconds of active recovery at 30% of their peak power output and a 2-minute cool-down at 50W for a total of 17.5 minutes.
Study: NCT04494321

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: Inhaled corticosteroid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: Inhaled corticosteroid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Inhaled corticosteroid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol
Description: Long Acting Beta Agonist (LABA)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol
Description: Long Acting Beta Agonist (LABA)
Study: NCT00827307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: In the combination arm, patients receive ZOLADEX 3.6 mg by subcutaneous injection every 4 weeks along with once-daily oral dose of tamoxifen 20 mg
Study: NCT01337310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesetaxel
Description: The starting dose for the first 3 patients treated will be 24 mg/m2. In the absence of dose-limiting toxicity, the dose will be increased by 3 mg/m2 for the next group of 3 patients treated. Interpatient dose escalation will continue in this manner to 27 and 31 mg/m2 until the maximum tolerated dose or the maximum dose allowed per protocol (31 mg/m2) is reached and 6 patients are treated at this dose.
Study: NCT03688763

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-i)
Description: CBT-i is an evidence-based treatment for insomnia. Participants will receive CBT-i via online program (Sleepio).
Study: NCT03464058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS172767 micronized capsules
Description: Oral capsules
Study: NCT04554186

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Paravertebral block
Description: Injection of bupivacaine in the thoracic Paravertebral space using ultrasound

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Place a fentanyl patch 50 microgram
Study: NCT02698345

Intervention type: DEVICE
Intervention: drug-eluting balloon (In.PACT Admiral, Medtronic)
Study: NCT04561115

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Gamunex-C
Description: Intravenous infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVIG-PEG
Description: Intravenous infusion.
Study: NCT02261181

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XONRID
Description: The patients will be treated with XONRID + standard of care (SOC) preemptive treatment adopted during radiation treatment for head and neck cancer patients. Patients will be instructed to apply the study cream (XONRID) on the irradiated area two times daily, the first application 1-2 h after the morning radiotherapy session, the second in the evening, starting on the first day of irradiation and continuing until 2 weeks after the completion of the radiation treatments or the development of Grade 3 or 4 skin toxicity. When G3 toxicity will occur the patient will be discontinued from the study medication and the skin toxicity will be managed according to internal guidelines.
Study: NCT00945438

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza virus vaccine 2009-2010 formulation
Description: 0.1 mL, Intradermal

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza virus vaccine 2009-2010 formulation
Description: 0.5 mL, Intradermal
Study: NCT04305535

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Peptidic+Probiotic
Description: Oligomeric oral nutritional supplement (Bi1 peptidic) and a mix of probiotics~* Bifidobacterium animalis subsp. lactis BPL1,~* Lactobacillus rhamnosus BPL15,~* Lactobacillus rhamnosus CNCM i-4036~* Bifidobacterium longum ES1

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Peptidic+Placebo
Description: Oligomeric oral nutritional supplement (Bi1 peptidic) and a placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Polymeric+Placebo
Description: Polymeric oral nutritional supplement and a placebo
Study: NCT00784095

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Life completion and preparation
Description: Subjects will discuss life review, issues of forgiveness and heritage and legacy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Subjects will listen to a non-guided relaxation CD.
Study: NCT04491838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pozelimab
Description: Single subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pozelimab
Description: Single subcutaneous (SC) injection
Study: NCT04303624

Intervention type: OTHER
Intervention: Health sciences survey
Description: Large scale demographic survey evaluating attitudes of population towards organ donation for the self vs. family
Study: NCT03220529

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brillouin Ocular Scanner

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brillouin Ocular Scanner
Study: NCT01310855

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cediranib maleate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cediranib maleate
Study: NCT03220529

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brillouin Ocular Scanner

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brillouin Ocular Scanner

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brillouin Ocular Scanner
Study: NCT00965510

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: care coordination
Description: patients receive care coordination to improve their type II diabetes
Study: NCT01310855

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gefitinib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo